Citation: | YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116 |
[1] |
Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
|
[2] |
Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
|
[3] |
National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
|
[4] |
National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
|
[5] |
National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
|
[6] |
National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
|
[7] |
National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
|
[8] |
National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
|
[9] |
National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
|
[10] |
National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
|
[11] |
NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
|
[12] |
NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
|
[13] |
NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
|
[14] |
National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
|
[15] |
Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
|
[16] |
NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
|
[17] |
National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
|
[1] | CHENG Xiaohong, JIANG Li, DONG Xingting, KANG Xiulin, LIU Lifang. Identification of chemical constituents in Fufang Shechuangzi Xiji(Lotion)by UPLC-Q-TOF-MS/MS[J]. Journal of China Pharmaceutical University, 2022, 53(4): 452-466. DOI: 10.11665/j.issn.1000-5048.20220408 |
[2] | WANG Jingyi, DONG Yangyang, QI Chulu, ZHANG Jiayao, ZHANG Minjie, WANG Hao. Chemical constituents of the stem bark of Bombax ceiba L.[J]. Journal of China Pharmaceutical University, 2016, 47(5): 570-574. DOI: 10.11665/j.issn.1000-5048.20160511 |
[3] | XU Yunhui, JIANG Xueyang, XU Jian, JIANG Renwang, ZHANG Jie, XIE Zijian, FENG Feng. Chemical constituents from Callicarpa kwangtungensis Chun[J]. Journal of China Pharmaceutical University, 2016, 47(3): 299-302. DOI: 10.11665/j.issn.1000-5048.20160309 |
[4] | MA Lin, ZHANG Rongfei, YU Shule, WU Zhengfeng, ZHAO Shouxun, Wang Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Chemical constituents of Fructus Gleditsiae Abnormalis[J]. Journal of China Pharmaceutical University, 2015, 46(2): 188-193. DOI: 10.11665/j.issn.1000-5048.20150209 |
[5] | LI Jiu-hui, CHEN Guang-ying, HAN Chang-ri, MO Zheng-rong, SONG Xiao-ping. Chemical constituents from the stems of Vatica mangachpoi Blanco[J]. Journal of China Pharmaceutical University, 2012, 43(1): 25-27. |
[6] | QU Wei, ZHAO Ling, LIANG Jing-yu. Chemical constituents from Saururus chinensis(Lour.) Baill[J]. Journal of China Pharmaceutical University, 2011, 42(6): 507-509. |
[7] | WANG Hang, FENG Fang, WANG Xue-qua. Chemical constituents of Zhizidahuang decoction detected by HPLC-PDA-ESI-MS/MS[J]. Journal of China Pharmaceutical University, 2009, 40(3): 232-237. |
[8] | Chemical Constituents ofDendrobium fimbriatum Hook.([J]. Journal of China Pharmaceutical University, 2001, (3): 42-44. |
[9] | Studies of Chemical Constituents of Ficus Carica L[J]. Journal of China Pharmaceutical University, 1996, (4): 13-15. |
[10] | COMPARISON BETWEEN THE OIL CONSTITUENTS OF WILD AND OF CULTIVATED A TRACTYLODES LANCEA BY GC/MS[J]. Journal of China Pharmaceutical University, 1989, (5): 289-290. |